Holen Sie sich die Stockscreener-App
58.51
0.95%
-0.56
Handel nachbörslich:
58.51
Schlusskurs vom Vortag:
$59.07
Offen:
$59.19
24-Stunden-Volumen:
1.18M
Relative Volume:
0.49
Marktkapitalisierung:
$11.25B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
21.75
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
-4.27%
1M Leistung:
-2.27%
6M Leistung:
+8.17%
1J Leistung:
-17.12%
1-Tages-Spanne:
$58.23
$60.71
1-Wochen-Bereich:
$58.23
$61.97
52-Wochen-Spanne:
$50.76
$73.18
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
58.51 | 11.36B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
EVP Of BioMarin Pharmaceutical Sold $996K In Stock - Benzinga
Jefferies Maintains Buy on BioMarin Pharmaceutical Inc. (BMRN) March 2026 - Meyka
BioMarin reports growth data for achondroplasia drug VOXZOGO - Investing.com South Africa
BioMarin reports growth data for achondroplasia drug VOXZOGO By Investing.com - Investing.com Nigeria
Jefferies reiterates Buy on BioMarin stock after DMD trial data - Investing.com
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical - PR Newswire
First Trust Advisors LP Raises Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Capital Research Global Investors Purchases 2,145,717 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Dimensional Fund Advisors LP Purchases 671,566 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BofA cuts BioMarin stock price target to $85 on Voxzogo outlook - Investing.com UK
BMRN: Strong 2025 growth, major 2026 clinical milestones, and Amicus acquisition drive future outlook - TradingView
BMRN: Strong 2025 growth, Amicus acquisition, and key 2026 clinical milestones drive optimism - TradingView
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $85.00 Price Target at Bank of America - MarketBeat
PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin (BMRN) - simplywall.st
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Korea Investment CORP - MarketBeat
Leerink Maintains Market Perform on BioMarin (BMRN) March 09, 2026 - Meyka
Leerink Partners reiterates Market Perform on BioMarin stock at $62 By Investing.com - Investing.com Australia
Leerink Partners reiterates Market Perform on BioMarin stock at $62 - Investing.com
Are Options Traders Aware of Insights on BMRN Stock That We Might Not Know? - Bitget
Do Options Traders Know Something About BMRN Stock We Don't? - Yahoo Finance
Earnings Beat: Is BioMarin Pharmaceutical Inc stock a value trapStop Loss & Technical Confirmation Trade Alerts - baoquankhu1.vn
BMRN: Strong 2025 growth, major pipeline milestones, and Amicus acquisition set to drive future value - TradingView
BMRN: Strong 2025 growth, robust pipeline, and Amicus acquisition set stage for future expansion - TradingView
WINTON GROUP Ltd Has $6.69 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Position Boosted by Vinva Investment Management Ltd - MarketBeat
Assessing BioMarin Pharmaceutical (BMRN) Valuation After FDA Expands PALYNZIQ Label For Pediatric PKU - Sahm
Rhenman & Partners Asset Management Boosts BioMarin Pharmaceutical Holdings - National Today
Rhenman & Partners Asset Management AB Has $10.11 Million Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Crossmark Global Holdings Inc. Has $4.02 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Why BioMarin Pharmaceutical Inc. stock could see breakout soonEarnings Performance Report & Stepwise Trade Signal Implementation - Naître et grandir
Fisher Asset Management LLC Has $1.72 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Details Strategy Refresh, Voxzogo Competition and 40% Margin Goal at TD Cowen Confab - MarketBeat
(BMRN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
FDA Extends Approval of PKU Drug to Include Adolescents - Medscape
Skeletal Dysplasia Market - GlobeNewswire Inc.
BioMarin Pharma: The Under-Two Strategy and New Market Ramps Shaping Voxzogo’s Next Chapter! - Smartkarma
Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight - Bolsamania
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients - AOL.com
Elo Mutual Pension Insurance Co Boosts BioMarin Pharmaceutical Holdings - National Today
Elo Mutual Pension Insurance Co Purchases 22,851 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Barclays raises BioMarin stock price target to $105 on acquisition By Investing.com - Investing.com UK
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
The kids are alright: Old drug from BioMarin scores key win in teensSan Francisco Business Times - The Business Journals
Barclays raises BioMarin stock price target to $105 on acquisition - Investing.com
Truist reiterates Buy on BioMarin stock amid new competition - Investing.com India
BioMarin Pharmaceutical Holdings Reduced by Rafferty Asset Management - National Today
Truist reiterates Buy on BioMarin stock amid new competition By Investing.com - Investing.com Nigeria
BioMarin stock price target raised to $105 by Freedom Capital on margin outlook - Investing.com Nigeria
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):